Table 1 Clinical characteristics of 341 patients
Characteristics | SUA after two cycles of IC > 327 μmol/L (%) | SUA after two cycles of IC ≤ 327 μmol/L (%) | PR/CR (%) | SD/PD (%) |
|---|---|---|---|---|
Total | 167 (49.0%) | 174 (51.0%) | 236 (69.2%) | 105 (30.8%) |
Gender | ||||
Female | 130 (38.1%) | 101 (29.6%) | 155 (45.5%) | 76 (22.3%) |
Male | 37 (10.9%) | 73 (21.4%) | 81 (23.7%) | 29 (8.5%) |
Age (years) | ||||
≤ 50 | 92 (27.0%) | 97 (28.4%) | 130 (38.1%) | 59 (17.3%) |
> 50 | 75 (22.0%) | 77 (22.6%) | 106 (31.1%) | 46 (13.5%) |
Pathological type | ||||
WHO I | 0 (0) | 2 (0.6%) | 0 (0) | 2 (0.6%) |
WHO II | 9 (2.6%) | 9 (2.6%) | 12 (3.5%) | 6 (1.8%) |
WHO III | 158 (46.3%) | 163 (47.8%) | 224 (65.7%) | 97 (28.4%) |
T stage | ||||
T1 | 24 (7.0%) | 17 (5.0%) | 28 (8.2%) | 13 (3.8%) |
T2 | 32 (9.4%) | 38 (11.1%) | 52 (15.2%) | 18 (5.3%) |
T3 | 65 (19.1%) | 72 (21.1%) | 99 (29.0%) | 38 (11.1%) |
T4 | 46 (13.5%) | 47 (13.8%) | 57 (16.7%) | 36 (10.6%) |
N stage | ||||
N0 | 11 (3.2%) | 7 (2.1%) | 11 (3.2%) | 7 (2.1%) |
N1 | 49 (14.4%) | 68 (19.9%) | 80 (23.5%) | 37 (10.9%) |
N2 | 87 (25.5%) | 79 (23.2%) | 115 (33.7%) | 51 (15.0%) |
N3 | 20 (5.9%) | 20 (5.9%) | 30 (8.8%) | 10 (2.9%) |
Chemotherapy cycles | ||||
≤ 3 | 31 (9.1%) | 31 (9.1%) | 41 (12.0%) | 21 (6.2%) |
> 3 | 136 (39.9%) | 143 (41.9%) | 195 (57.2%) | 84 (24.6%) |